A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study

The Pathophysiology and Treatment of Glaucoma

(2014) Robert N. Weinreb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rho-kinase inhibitors offer a new approach in the treatment of glaucoma

(2013) Pratap Challa et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma

(2012) Jean-François Rouland et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

An Evaluation of Therapeutic Noninferiority of 0.005% Latanoprost Ophthalmic Solution and Xalatan in Patients With Glaucoma or Ocular Hypertension

(2012) Maurizio Digiuni et al.   JOURNAL OF GLAUCOMA

A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

(2012) David Eveleth et al.   BMC Ophthalmology

Latanoprost 0.005% Test Formulation is as Effective as Xalatan® in Patients with Ocular Hypertension and Primary Open-Angle Glaucoma

(2011) Catherine Allaire et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2α agonist, in preclinical models

(2011) Achim H.P. Krauss et al.   EXPERIMENTAL EYE RESEARCH

Effect of nitric oxide compounds on monkey ciliary muscle in vitro

(2010) B’Ann T. Gabelt et al.   EXPERIMENTAL EYE RESEARCH

Activation of the BKCa Channel Increases Outflow Facility and Decreases Trabecular Meshwork Cell Volume

(2009) William M. Dismuke et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel

(2008) William M. Dismuke et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY